Source comparison
CJC-1295 No DAC & Ipamorelin: Research Protocol Comparison
CJC-1295 No DAC GHRH receptor agonist. Binds pituitary somatotrophs to stimulate endogenous GH pulse amplitude 30 minutes 100–200mcg, 1–3× daily GH pulse amplitude via serial sampling every 20 min over 4-hour window 2–8°C, use within 28 days, light protection
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- GHRH receptor agonist. Binds pituitary somatotrophs to stimulate endogenous GH pulse amplitude
- 30 minutes
- 100–200mcg, 1–3× daily
- GH pulse amplitude via serial sampling every 20 min over 4-hour window
- 2–8°C, use within 28 days, light protection mandatory
- Short half-life mimics physiological pulsatility. Ideal for circadian rhythm studies but requires frequent dosing
- Ipamorelin
- GHS-R1a selective agonist. Triggers ghrelin pathway without cortisol or prolactin elevation
- 2 hours
- 200–300mcg, 2–3× daily
- IGF-1 levels (fasted morning draw), GH secretion frequency
- 2–8°C, use within 28 days, bacteriostatic water preservative essential
- Selective receptor activation avoids ACTH stimulation seen in GHRP-6. Cleaner GH response with minimal metabolic interference
- Combination Protocol
- Synergistic. CJC amplifies pulse magnitude, ipamorelin increases pulse frequency and protects against desensitisation
- Combined: 30 min–2 hours
- Both peptides同時 administered 2–3× daily
- Combined GH AUC, body composition via DEXA, nitrogen retention
- Individual vials stored separately at 2–8°C; mix immediately before injection
- 3.2× greater GH AUC vs monotherapy in published trials. Combination is research standard for maximal secretagogue effect